This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: CardioOncology - Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with Osimertinib
Released: Mar 17, 2020
Commentary by Dr. Katherine Ruddy
JACC: CardioOncology - Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with Osimertinib
00:00:00
